And are there hints that the Bridge program is boosting GLP-1 scripts?
And the latest lawsuit pushing back on a new Lilly 340B is a great example of “safety-net cosplay”
It's a short Curve in hopes that you're enjoying a long weekend
And no one really thinks the tariff proposal is likely to achieve the goal of onshoring manufacturing, either
Plus Trump pledges 100% tariffs on generic meds ... but the tariffs wouldn’t kick in until his term is nearly over
And UnitedHealth Group’s revenues topped $100 billion -- again -- last quarter
Plus TrumpRx’s June site visits sunk to their lowest level since the site launched in February
“This is the first time that we’ve seen significant restrictions on access to drugs that are safe and effective.”
And that lawsuit includes a surprising level of detail on 340B prices
And Lilly bakes the CMS Bridge demo into its ad campaigns
Plus assessing whether CMS’ Bridge program will be ginormous or merely huge
And trying to make sense of an ADA poll showing that most patients with diabetes pay more than $35 a month for insulin
And drug launch prices fell like a rock last year (but you can’t really read anything into that)
And pharma companies take aim at the reluctance of European countries to boost medicine spending
And a 340B hospital in Virginia finds a novel way of not helping vulnerable patients
Plus a couple of 340B links and a study on the impact of the Medicare Part D out-of-pocket cap
